Table 4 The relationship between clinical characteristics and cytotoxicity of the regimens combining chidamide with IDA in primary refractory or relapsed CD34⁺ AML cells

Status

Refractory (n = 7)

25.86 ± 8.36

34.30 ± 11.07

53.84 ± 18.84

70.00 ± 13.96

0.732

Relapse (n = 5)

26.20 ± 7.74

31.52 ± 7.47

49.21 ± 15.93

72.00 ± 7.64

WBC

>30 (n = 6)

27.54 ± 9.79

36.05 ± 11.21

58.28 ± 18.96

76.63 ± 9.60

0.016*

(×10⁹/l)

<30 (n = 6)

24.46 ± 5.50

30.24 ± 7.10

45.54 ± 13.60

65.00 ± 10.46

Karyotype

Non-complex (n = 8)

25.36 ± 9.57

31.61 ± 10.84

49.45 ± 16.28

68.62 ± 11.37

0.178

Complex (n = 4)

27.30 ± 1.64

36.19 ± 5.89

56.83 ± 20.07

75.17 ± 11.50

LDH

Normal (n = 6)

24.77 ± 6.94

30.88 ± 7.39

50.48 ± 16.02

66.97 ± 9.98

0.221

High (n = 6)

27.24 ± 8.94

35.41 ± 11.37

53.34 ± 19.49

74.65 ± 12.16

Total

26.00 ± 7.74

33.14 ± 9.45

51.91 ± 17.08

70.81 ± 11.34

<0.01